Evidence map›Paper›PMID 37354070›Full record

ArticleCancer2023

Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.

Neal S McCall, James R Janopaul-Naylor, H Scott McGinnis, Aparna H Kesarwala, Sibo Tian, William A Stokes, Joseph W Shelton, Conor E Steuer, Jennifer W Carlisle, Ticiana A Leal and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Neal S McCallDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-7571-6984
James R Janopaul-NaylorDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-3612-4852
H Scott McGinnisDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Aparna H KesarwalaDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Sibo TianDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-5018-4854
William A StokesDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Joseph W SheltonDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Conor E SteuerDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Jennifer W CarlisleDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-7085-4640
Ticiana A LealDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-3735-9063
Suresh S RamalingamDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0757-3106
Jeffrey D BradleyDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Kristin A HigginsDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

backgroundThe PACIFIC trial established consolidative durvalumab after concurrent chemoradiation as standard-of-care in patients with stage III or unresectable non-small cell lung cancer (NSCLC). Black patients, however, comprised just 2% (n = 14) of randomized patients in this trial, warranting real-world evaluation of the PACIFIC regimen in these patients.

methodsThis single-institution, multi-site study included 105 patients with unresectable stage II/III NSCLC treated with concurrent chemoradiation followed by durvalumab between 2017 and 2021. Overall survival (OS), progression-free survival (PFS), and grade ≥3 pneumonitis-free survival (PNFS) were compared between Black and non-Black patients using Kaplan-Meier and Cox regression analyses.

resultsA total of 105 patients with a median follow-up of 22.8 months (interquartile range, 11.3-37.3 months) were identified for analysis, including 57 Black (54.3%) and 48 (45.7%) non-Black patients. The mean radiation prescription dose was higher among Black patients (61.5 ± 2.9 Gy vs. 60.5 ± 1.9 Gy; p = .031), but other treatment characteristics were balanced between groups. The median OS (not-reached vs. 39.7 months; p = .379) and PFS (31.6 months vs. 19.3 months; p = .332) were not statistically different between groups. Eight (14.0%) Black patients discontinued durvalumab due to toxicity compared to 13 (27.1%) non-Black patients (p = .096). The grade ≥3 pneumonitis rate was similar between Black and non-Black patients (12.3% vs. 12.5%; p = .973), and there was no significant difference in time to grade ≥3 PNFS (p = .904). Three (5.3%) Black patients and one (2.1%) non-Black patient developed grade 5 pneumonitis.

conclusionsThe efficacy and tolerability of consolidative durvalumab after chemoradiation appears to be comparable between Black and non-Black patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPneumoniaAntibodies, MonoclonalChemoradiotherapyHumansAntibodies, Monoclonaldurvalumabchemoradiationdurvalumabimmunotherapynon-small cell lung cancerrace

Identifiers

PMID37354070
PMCPMC13051214
OpenAlexW4381849158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.